NSPR logo

NSPR
InspireMD Inc

34,529
Mkt Cap
$81.78M
Volume
15,596.00
52W High
$3.80
52W Low
$1.59
PE Ratio
-2.27
NSPR Fundamentals
Price
$1.91
Prev Close
$1.93
Open
$1.93
50D MA
$2.17
Beta
0.40
Avg. Volume
204,758.63
EPS (Annual)
-$0.7633
P/B
1.25
Rev/Employee
$81,500.00
Loading...
Loading...
News
all
press releases
InspireMD (NYSE:NSPR) Shares Up 2% - Should You Buy?
InspireMD (NYSE:NSPR) Trading 2% Higher - Here's Why...
MarketBeat·8d ago
News Placeholder
More News
News Placeholder
InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates
InspireMD (NSPR) delivered earnings and revenue surprises of 0.00% and +31.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·30d ago
News Placeholder
Hologic (HOLX) Q4 Earnings and Revenues Beat Estimates
Hologic (HOLX) delivered earnings and revenue surprises of +2.73% and +1.49%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Intuitive Surgical, Inc. (ISRG) Q3 Earnings and Revenues Top Estimates
Intuitive Surgical (ISRG) delivered earnings and revenue surprises of +20.60% and +3.92%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
CVRx (CVRX) Surges 19.0%: Is This an Indication of Further Gains?
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·5mo ago
News Placeholder
InspireMD Launches CGuard Prime Carotid Stent System in the U.S.
NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention.
Zacks·5mo ago
News Placeholder
InspireMD Stock Dips On Wider-Than-Expected Q1 Loss, But Retail Is Optimistic
The company’s revenue increased marginally to $1.52 million, driven by the continued adoption of its CGuard technology in existing markets.
Stocktwits·7mo ago
News Placeholder
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of stroke, today...
Globe Newswire·2y ago
News Placeholder
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of stroke, today...
Globe Newswire·2y ago
News Placeholder
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
- Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company's ongoing U.S. Investigational Device...
Globe Newswire·2y ago

Latest NSPR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.